PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen
P.R. Maran, A. Aiello, M.R. Magrì, C. Alberti, E. Visentin, F. Venturini, G. ScroccaroVolume:
15
Year:
2012
Language:
english
DOI:
10.1016/j.jval.2012.08.2123
File:
PDF, 59 KB
english, 2012